TMS for Anorexia
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores a new treatment for anorexia nervosa using transcranial magnetic stimulation (TMS), which uses magnetic fields to stimulate specific brain areas. Anorexia nervosa is a serious condition characterized by a distorted body image and fear of weight gain, often resulting in severe weight loss. The trial seeks to determine if TMS can alter certain brain circuits associated with these symptoms and improve behaviors related to anorexia. It includes two groups: one receiving active TMS and another receiving a sham treatment that mimics the real one. Females aged 18 to 45 with a current diagnosis of anorexia nervosa and no significant health issues may be suitable for this trial. As an unphased trial, this study offers participants the chance to contribute to groundbreaking research that could lead to new treatments for anorexia nervosa.
Will I have to stop taking my current medications?
The trial requires that participants do not take more than 2 mg of lorazepam daily or any anticonvulsants, and they cannot be on certain antidepressants like bupropion, tricyclic antidepressants, or neuroleptics. If you are on these medications, you may need to stop or adjust them to participate.
What prior data suggests that this TMS treatment is safe for anorexia nervosa?
Research has shown that transcranial magnetic stimulation (TMS) is generally safe for people with anorexia nervosa. Studies have found that TMS can improve symptoms with only minor and short-lived side effects, such as mild headaches or scalp discomfort, which typically do not last long.
Previous research suggests that TMS is well-tolerated, with most people not experiencing serious negative reactions. Although larger studies are still needed for more detailed information, current evidence supports TMS as a safe option for treating anorexia.12345Why are researchers excited about this trial?
Researchers are excited about the rTMS treatment using the BrainsWay Model 104 system for anorexia because it offers a non-invasive approach that directly targets brain activity. Unlike traditional treatments such as psychotherapy and medication, this method uses a specialized H1-Coil to deliver repetitive transcranial magnetic stimulation (rTMS) to specific areas of the brain, potentially altering neural pathways involved in anorexia. The technique's precision in targeting the left dorsolateral prefrontal cortex (DLPFC) could lead to more rapid and effective symptom relief. Additionally, the use of a sham comparator in the trial helps to rigorously test the treatment's true efficacy, adding to the excitement about its potential impact.
What evidence suggests that TMS might be an effective treatment for anorexia?
Research has shown that transcranial magnetic stimulation (TMS) can help people with anorexia nervosa. One study found that TMS improved body mass index (BMI) and reduced key symptoms of the disorder. Another study observed changes in brain blood flow related to weight changes after TMS treatment. Overall, TMS is considered safe and has shown positive results, such as reducing cravings and behaviors related to food. In this trial, participants will be assigned to either an active TMS treatment arm or a sham TMS comparator arm. These findings suggest that TMS might help change brain circuits linked to anorexia, potentially improving eating habits and body image.12345
Who Is on the Research Team?
Guido Frank, MD
Principal Investigator
University of California, San Diego
Are You a Good Fit for This Trial?
This trial is for English-speaking females aged 18 to 45 with Anorexia Nervosa as per DSM V, either restricting or binge/purge subtype. Participants must not be pregnant, have metal implants near the head, major medical illnesses, substance abuse issues in the last month, certain psychiatric disorders, abnormal blood tests results or a history of seizures among other exclusions.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive iTBS treatment over 1 week for active group or 2 weeks for sham/active group
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- rTMS treatment using BrainsWay Model 104 system with H1-Coil
- sham TMS using BrainsWay Model 104 system with H1-Coil
Trial Overview
The study is testing Transcranial Magnetic Stimulation (TMS) using BrainsWay Model 104 system with H1-Coil to see if it can change brain activity and improve symptoms of Anorexia Nervosa. Some participants will receive real TMS while others get sham TMS without active treatment for comparison.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Placebo Group
rTMS treatments will employ the Brainsway stimulator (Brainsway Ltd, Israel). Prior to the first treatment (no more than 5 days prior), each subject's motor threshold (MT) will first be determined according to published methods (Schutter, van Honk, 2006; Julkunen et al, 2009). This location, as well as the stimulation target spot, will be marked at the first session on the scalp and standard methods will be used to target this spot during treatment sessions. The modified BeamF3 scalp heuristic will be used to localize the treatment site over the left DLPFC (Mir-Moghtadaei et al., 2015). Subjects will complete 5 treatments days. A treatment day will consist of 10 treatment sessions with the start of each session timed to be at least 50 minutes from the previous session.
The BrainsWay Model 104 with H4 coil has an integrated sham coil. The sham condition will start with the same clicking noise as the active TMS condition. Every helmet has a corresponding sham H-coil encased in the same helmet. The sham coil induces only a negligible sub-threshold field in the brain while making an identical noise and inducing some scalp sensation. Subjects will complete 5 treatments days. A treatment day will consist of 10 treatment sessions with the start of each session timed to be at least 50 minutes from the previous session. Subjects in this arm will have the option of receiving the Active iTBS protocol after they complete the 5 days of 10 daily treatment sessions.
rTMS treatment using BrainsWay Model 104 system with H1-Coil is already approved in United States, European Union for the following indications:
- Major Depressive Disorder
- Obsessive-Compulsive Disorder
- Major Depressive Disorder
- Obsessive-Compulsive Disorder
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of California, San Diego
Lead Sponsor
Published Research Related to This Trial
Citations
Efficacy of transcranial magnetic stimulation in anorexia nervosa
TMS represents an effective therapy for patients with AN, leading to improvements in both BMI and core symptoms of AN, with minor and transient side effects.
Is Repetitive Transcranial Magnetic Stimulation (RTMS) a ...
The analyses show that rTMS induced large improvements in body mass index (BMI) among obese individuals. Null clinical effects have been detected for primary ...
A pilot study exploring the effect of repetitive transcranial ...
This exploratory pilot study identified rTMS treatment related changes in CBF in adults with SE-AN and these were associated with changes in weight.
Repetitive Transcranial Magnetic Stimulation Strategies in ...
Findings indicated that rTMS is safe for patients with anorexia nervosa and well tolerated, but large randomized controlled trials comparing ...
Repetitive transcranial magnetic stimulation in the ...
In this review, some studies showed relatively positive results with safe outcomes and with reduction of both craving and eating behaviors with active ...
Other People Viewed
By Subject
By Trial
Related Searches
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.